Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Aldeyra Therapeutics Inc. buy stratec

Start price
€6.86
27.01.18 / 50%
Target price
€11.73
04.11.21
Performance (%)
15.24%
End price
€7.90
05.11.21
Summary
This prediction ended on 05.11.21 with a price of €7.90. The BUY prediction by stratec finished with a performance of 15.24%. stratec has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Aldeyra Therapeutics Inc. 6.217% 6.217% -65.946% -
iShares Core DAX® 2.149% 5.415% 21.385% 22.595%
iShares Nasdaq 100 0.838% 1.926% 44.386% 55.330%
iShares Nikkei 225® 1.143% 2.887% 27.641% 9.481%
iShares S&P 500 1.265% 3.698% 33.327% 49.646%

Comments by stratec for this prediction

In the thread Aldeyra Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) 15.24%
Target price 11.726
Change
Ends at 04.11.21

Aldeyra multiple trials are set to read out in the second half of the year


Convincing data has been generated to date, and multiple trials are set to read out in the second half of the year, which will likely lead to a run-up.


Key points to the original bullish thesis included the following:



  • The valuation of the company paled in comparison to the sheer size of the opportunity being targeted in the Dry Eye Disease market ($1.8 billion in prescription sales in 2016). The lengths that Allergan (NYSE:AGN) went to try to protect IP for its blockbuster eye treatment Restasis was proof enough of how valuable the DED market is.
  • Topical ocular candidate ADX-102 generated encouraging data in a mid-stage study in patients with dry eye disease, with significant improvements recorded across a variety of measures (high statistical significance). Improvements in signs and symptoms of the disease were clear within the first week of therapy and a dose response was observed, with activity increasing throughout the time patients were being treated.
  • A potential point of differentiation as compared to other approved dry eye treatments was that ADX-102 reduced levels of pro-inflammatory aldehyde mediator malondialdehyde in patients' tears.
  • Lastly, there was more to this story than dry eye disease, as a pivotal study of ADX-102 in allergic conjunctivitis was in the works following feedback from regulatory agencies. The drug could address an adequate response to antihistamines, which affects around one-third of allergic conjunctivitis patients (worldwide prevalence of 20% to 40% of population). Also, results from its phase 3 program in noninfectious anterior uveitis were expected in the second half of 2018 along with preliminary results from a pivotal study in Sjögren-Larsson Syndrome (no FDA approved therapies for the latter).





In the thread Trading Aldeyra Therapeutics Inc.
Prediction Buy
Perf. (%) 15.24%
Target price 11.726
Change
Ends at 04.11.21

Die von stratec gewählte maximale Laufzeit wurde überschritten